<code id='DE1D5F0F3F'></code><style id='DE1D5F0F3F'></style>
    • <acronym id='DE1D5F0F3F'></acronym>
      <center id='DE1D5F0F3F'><center id='DE1D5F0F3F'><tfoot id='DE1D5F0F3F'></tfoot></center><abbr id='DE1D5F0F3F'><dir id='DE1D5F0F3F'><tfoot id='DE1D5F0F3F'></tfoot><noframes id='DE1D5F0F3F'>

    • <optgroup id='DE1D5F0F3F'><strike id='DE1D5F0F3F'><sup id='DE1D5F0F3F'></sup></strike><code id='DE1D5F0F3F'></code></optgroup>
        1. <b id='DE1D5F0F3F'><label id='DE1D5F0F3F'><select id='DE1D5F0F3F'><dt id='DE1D5F0F3F'><span id='DE1D5F0F3F'></span></dt></select></label></b><u id='DE1D5F0F3F'></u>
          <i id='DE1D5F0F3F'><strike id='DE1D5F0F3F'><tt id='DE1D5F0F3F'><pre id='DE1D5F0F3F'></pre></tt></strike></i>

          knowledge

          knowledge

          author:knowledge    Page View:44453
          Janet Woodcock -- health policy coverage from STAT
          Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

          WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

          Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

          advertisement

          Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more
          New weight loss drugs work. But how can they best be used?
          New weight loss drugs work. But how can they best be used?

          SteffenTrumpf/picturealliance/GettyImagesLONDON—Startinginthenewyear,ateamofresearchersintheU.K.andD

          read more
          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more

          Burning questions for the 2024 JPM Healthcare Conference

          AlexHogan/STATTheJ.P.MorganHealthcareConferenceisuponus,bringingitsfreneticmeetings,crowdedhallways,